| |
|
|
|
|
|
|
|
|
1. |
Record Nr. |
UNISA990003389290203316 |
|
|
Titolo |
Optical properties of condensed matter / edited by Jai Sing |
|
|
|
|
|
Pubbl/distr/stampa |
|
|
Chichester : Jon Wiley & Sons, 2006 |
|
|
|
|
|
|
|
ISBN |
|
|
|
|
|
|
Descrizione fisica |
|
|
|
|
|
|
Collana |
|
Wiley series in materials for electronic and optoelectronic application |
|
|
|
|
|
|
Disciplina |
|
|
|
|
|
|
Soggetti |
|
Solidi - Proprietà fisiche |
|
|
|
|
|
|
Collocazione |
|
|
|
|
|
|
Lingua di pubblicazione |
|
|
|
|
|
|
Formato |
Materiale a stampa |
|
|
|
|
|
Livello bibliografico |
Monografia |
|
|
|
|
|
2. |
Record Nr. |
UNINA9910483140803321 |
|
|
Autore |
de Graaf Jacqueline |
|
|
Titolo |
ApoB in Clinical Care / / by Jacqueline de Graaf, Patrick Couture, Allan Sniderman |
|
|
|
|
|
|
|
Pubbl/distr/stampa |
|
|
Houten : , : Bohn Stafleu van Loghum : , : Imprint : Bohn Stafleu van Loghum, , 2015 |
|
|
|
|
|
|
|
|
|
ISBN |
|
|
|
|
|
|
Edizione |
[1st ed. 2015.] |
|
|
|
|
|
Descrizione fisica |
|
1 online resource (183 p.) |
|
|
|
|
|
|
Disciplina |
|
|
|
|
|
|
Soggetti |
|
|
|
|
|
|
Lingua di pubblicazione |
|
|
|
|
|
|
Formato |
Materiale a stampa |
|
|
|
|
|
Livello bibliografico |
Monografia |
|
|
|
|
|
Note generali |
|
Description based upon print version of record. |
|
|
|
|
|
|
Nota di bibliografia |
|
Includes bibliographical references. |
|
|
|
|
|
|
Nota di contenuto |
|
Table of contents; Foreword; About the authors; List of abbreviations; 1. The Life History of ApoB Lipoprotein Particles; 1.1 Physiology of the ApoB Lipoprotein Particles; 1.1.1 Introduction; 1.1.2 Anatomy of the ApoB48 and ApoB100 Lipoprotein Particles; 1.1.3 The ApoB48 |
|
|
|
|
|
|
|
|
|
|
|
Lipoprotein Particles: Chylomicrons and Chylomicron Remnants Physiological Role; 1.1.4 The ApoB100 Lipoproteins Particles: VLDL, IDL, LDL; 1.1.5 Lipoprotein(a); 1.2 Heterogeneity in the ApoB Lipoprotein Particles; 1.2.1 Introduction; 1.2.2 VLDL Heterogeneity; 1.2.3 LDL Heterogeneity |
1.2.4 The Atherogenic Lipoprotein Phenotype1.3 The Fatty Acid Cycle and the ApoB Lipoprotein Particles; 1.3.1 Introduction; 1.3.2 FA Flux and the Adipocyte - the Role of ApoB48 and ApoB100 Lipoproteins; 1.3.3 Fatty Acid Flux in Hepatocytes; Summary; 1.4 The Hepatic Cholesterol Cycle and Regulation of ApoB Lipoprotein Particles; 1.4.1 Introduction; 1.4.2 Total Body Cholesterol Balance; 1.4.3 Regulation of Cholesterol Homeostasis in the Liver; 1.4.4 Regulation of LDL Particle Number in Plasma; 2. Diagnosis of the ApoB Dyslipo-proteinemias: The ApoB Algorithm; 2.1 Introduction |
2.2 The ApoB Diagnostic Algorithm HyperapoB: ApoB = 1.2 g/l versus NormoapoB: ApoB < 1.2 g/l; NormoapoB: NormoTG < 1.5 mmol/l versus HyperTG = 1.5 mmol/l; NormoTG NormoapoB; HyperTG NormoapoB: TG/ApoB = 10; HyperTG NormoapoB: TG/apoB = 10 and apoB = 0.75 g/l; HyperTG NormoapoB: TG/apoB = 10 and apoB < 0.75 g/l; HyperTG NormoapoB: TG/ApoB < 10; HyperTG NormoapoB: TG/ApoB < 10 and TC/ApoB = 6.2; HyperTG NormoapoB: TG/ApoB < 10 and TC/ApoB < 6.2; NormoTG HyperapoB: ApoB = 1.2 g/l and TG < 1.5 mmol/l; HyperTG HyperapoB: ApoB = 1.2 g/l and TG = 1.5 mmol/l |
2.3 Limitations of any Diagnostic Algorithm3. The Primary ApoB Dyslipoproteinemias; 3.1 HyperTG NormoapoB; 3.1.1 HyperTG NormoapoB due to Increased Chylomicron Particles; 3.1.2 HyperTG NormoapoB due to Elevated Chylomicrons and VLDL Particles; 3.1.3 HyperTG NormoapoB due to Remnant Lipoprotein Disorder; 3.1.4 HyperTG NormoapoB due to Increased VLDL; 3.2 HyperTG HyperapoB due to Increased VLDL and LDL Particles; 3.2.1 Familial Combined Hyperlipidemia (FCH); 3.2.2 Sitosterolemia; 3.3.1 Severe Hypercholesterolemic Phenotype; 3.3.2 Treatment of the Severe Hypercholesterolemic Phenotypes |
3.3.3 Polygenic Hypercholesterolemia3.3.4 CYP7A1 Deficiency; 3.3.5 Hypoalphalipoproteinemia; 3.3.6 Cholesteryl Ester Storage Disease (CESD); 3.3.7 Hypercholesterolemic NormoapoB Phenotype; 4. Secondary ApoB Dyslipoproteinemias; 4.1 Introduction; 4.2 Type 2 Diabetes Mellitus, Metabolic Syndrome, Abdominal Obesity; 4.2.1 HyperTG HyperapoB: Increased VLDL and LDL Lipoprotein Particles; 4.2.2 HyperTG NormoapoB: Increased VLDL Lipoprotein Particles; 4.2.3 HyperTG NormoapoB: Increased Chylomicron and VLDL Lipoprotein Particles |
4.2.4 HyperTG NormoapoB: Increased Chylomicron and VLDL Remnant Lipoprotein particles |
|
|
|
|
|
|
Sommario/riassunto |
|
Now, based on the apoB algorithm, that is outlined and illustrated in this book, family physicians as well as cardiologists, endocrinologists and internists will be able to easily and accurately identify and treat these disorders. The apoB dyslipoproteinemias are major common causes of vascular disease. But until now, accurate diagnosis has not been possible. With just total cholesterol, triglycerides and apoB, all the apoB dyslipoproteinemias, with the exception of elevated Lp(a), can be identified using the apoB algorithm. The apoB app, which incorporates this algorithm, is available from both Apple and Android and is free. . |
|
|
|
|
|
|
|
| |